RESUMEN
Organoids are carrying the promise of modeling complex disease phenotypes and serving as a powerful basis for unbiased drug screens, potentially offering a more efficient drug-discovery route. However, unsolved technical bottlenecks of reproducibility and scalability have prevented the use of current organoids for high-throughput screening. Here, we present a method that overcomes these limitations by using deep-learning-driven analysis for phenotypic drug screens based on highly standardized micropattern-based neural organoids. This allows us to distinguish between disease and wild-type phenotypes in complex tissues with extremely high accuracy as well as quantify two predictors of drug success: efficacy and adverse effects. We applied our approach to Huntington's disease (HD) and discovered that bromodomain inhibitors revert complex phenotypes induced by the HD mutation. This work demonstrates the power of combining machine learning with phenotypic drug screening and its successful application to reveal a potentially new druggable target for HD.
Asunto(s)
Aprendizaje Profundo , Enfermedad de Huntington , Humanos , Enfermedad de Huntington/tratamiento farmacológico , Ensayos Analíticos de Alto Rendimiento , Evaluación Preclínica de Medicamentos , Reproducibilidad de los Resultados , OrganoidesRESUMEN
PURPOSE: This executive summary of a national living guideline aims to provide rapid evidence based recommendations on the role of drug interventions in the treatment of hospitalized patients with COVID-19. METHODS: The guideline makes use of a systematic assessment and decision process using an evidence to decision framework (GRADE) as recommended standard WHO (2021). Recommendations are consented by an interdisciplinary panel. Evidence analysis and interpretation is supported by the CEOsys project providing extensive literature searches and living (meta-) analyses. For this executive summary, selected key recommendations on drug therapy are presented including the quality of the evidence and rationale for the level of recommendation. RESULTS: The guideline contains 11 key recommendations for COVID-19 drug therapy, eight of which are based on systematic review and/or meta-analysis, while three recommendations represent consensus expert opinion. Based on current evidence, the panel makes strong recommendations for corticosteroids (WHO scale 5-9) and prophylactic anticoagulation (all hospitalized patients with COVID-19) as standard of care. Intensified anticoagulation may be considered for patients with additional risk factors for venous thromboembolisms (VTE) and a low bleeding risk. The IL-6 antagonist tocilizumab may be added in case of high supplemental oxygen requirement and progressive disease (WHO scale 5-6). Treatment with nMABs may be considered for selected inpatients with an early SARS-CoV-2 infection that are not hospitalized for COVID-19. Convalescent plasma, azithromycin, ivermectin or vitamin D3 should not be used in COVID-19 routine care. CONCLUSION: For COVID-19 drug therapy, there are several options that are sufficiently supported by evidence. The living guidance will be updated as new evidence emerges.
Asunto(s)
COVID-19 , COVID-19/terapia , Hospitalización , Humanos , Inmunización Pasiva , Guías de Práctica Clínica como Asunto , SARS-CoV-2 , Sueroterapia para COVID-19Asunto(s)
Antibacterianos/farmacología , Infecciones por Mycobacterium no Tuberculosas/tratamiento farmacológico , Mycobacterium abscessus/efectos de los fármacos , Línea Celular Tumoral , Sistemas de Liberación de Medicamentos/métodos , Evaluación Preclínica de Medicamentos/métodos , Células Hep G2 , Humanos , Pruebas de Sensibilidad Microbiana , Mycobacterium tuberculosis/efectos de los fármacos , Micobacterias no Tuberculosas/efectos de los fármacosRESUMEN
INTRODUCTION: Complications after cholecystectomy are continuously documented in a nationwide database in Germany. Recent studies demonstrated a lack of reliability of these data. The aim of the study was to evaluate the impact of a control algorithm on documentation quality and the use of routine diagnosis coding as an additional validation instrument. METHODS: Completeness and correctness of the documentation of complications after cholecystectomy was compared over a time interval of 12 months before and after implementation of an algorithm for faster and more accurate documentation. Furthermore, the coding of all diagnoses was screened to identify intraoperative and postoperative complications. RESULTS AND DISCUSSION: The sensitivity of the documentation for complications improved from 46 % to 70 % (p = 0.05, specificity 98 % in both time intervals). A prolonged time interval of more than 6 weeks between patient discharge and documentation was associated with inferior data quality (incorrect documentation in 1.5 % versus 15 %, p < 0.05). The rate of case documentation within the 6 weeks after hospital discharge was clearly improved after implementation of the control algorithm. Sensitivity and specificity of screening for complications by evaluating routine diagnoses coding were 70 % and 85 %, respectively. The quality of documentation was improved by implementation of a simple memory algorithm.
Asunto(s)
Colecistectomía , Documentación/normas , Complicaciones Intraoperatorias/diagnóstico , Sistemas de Registros Médicos Computarizados/legislación & jurisprudencia , Sistemas de Registros Médicos Computarizados/normas , Complicaciones Posoperatorias/diagnóstico , Garantía de la Calidad de Atención de Salud/normas , Mejoramiento de la Calidad/normas , Algoritmos , Benchmarking/legislación & jurisprudencia , Benchmarking/normas , Codificación Clínica/legislación & jurisprudencia , Codificación Clínica/normas , Recolección de Datos/legislación & jurisprudencia , Recolección de Datos/normas , Alemania , Humanos , Programas Nacionales de Salud/legislación & jurisprudencia , Programas Nacionales de Salud/normas , Sistemas de Información en Quirófanos/legislación & jurisprudencia , Sistemas de Información en Quirófanos/normas , Garantía de la Calidad de Atención de Salud/legislación & jurisprudencia , Mejoramiento de la Calidad/legislación & jurisprudencia , Programas InformáticosRESUMEN
There is no music in nature. Music is a purely human/psychologic phenomenon. Corresponding to the psyche it is bivalent, bipolar, dialectic, good and evil. A paradigm for this is the history of the organ.